Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27424349 | 0.91 | SLC6A2 (0.43) | SLC6A2SLC6A4ELANEMEN1KMT2A | |
| SCHEMBL29728493 | 0.91 | MAPK1 (0.37) | SLC6A2SLC6A4MEN1KMT2AHTR2A | |
| SCHEMBL22286550 | 0.91 | MAPK1 (0.37) | SLC6A2SLC6A4MEN1KMT2AHTR2A | |
| SCHEMBL19279084 | 0.90 | SLC6A2 (0.40) | SLC6A2SLC6A4ELANEALDH1A1NPSR1 | |
| SCHEMBL21585946 | 0.89 | SLC6A2 (0.35) | SLC6A2PTPN1MAPK1 | |
| SCHEMBL22502854 | 0.89 | SLC6A2 (0.34) | SLC6A2SLC6A4ALDH1A1NPSR1PTPN1 | |
| SCHEMBL21586104 | 0.88 | SLC6A2 (0.34) | SLC6A2SLC6A4HTR2A | |
| SCHEMBL29741888 | 0.88 | SLC6A2 (0.34) | SLC6A2SLC6A4HTR2A | |
| SCHEMBL29383907 | 0.87 | MAPK1 (0.36) | SLC6A2SLC6A4ELANEMEN1KMT2A | |
| SCHEMBL22286435 | 0.87 | MAPK1 (0.36) | SLC6A2SLC6A4ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | SLC6A2 166/4885SLC6A4 303/4885ELANE 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.